echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > HA344 provides potential treatment pathways for patients with CMM and a variety of different cancers

    HA344 provides potential treatment pathways for patients with CMM and a variety of different cancers

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Overcoming acquired drug resistance is a major challenge in cancer treatment


    The acquired resistance of cancer cells to treatment is a major challenge in patient management and treatment


    Skin metastatic melanoma (CMM) is the deadliest skin cancer


    Studies on the resistance of melanoma to vermolafenib or daprafenib (BRAFV600E inhibitor) and MEK inhibitors have revealed highly heterogeneous processes, most of which lead to the reactivation of MAPK signaling


    In addition to affecting resistance, metabolism also profoundly affects the development of primary tumors


    Heat map of A375R#1 and A375R#2 cell death induced by HA 344 and Vemu

    Image source: https://pubmed.


    In this study, the authors used a chemical procedure to generate derivatives of 5-aminoimidazole-4-carboxamide ribonucleotide, an AMPK activator and energy balance disruptor


    references

    Marwa Zerhouni et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.